1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 5,280 | 5,480 | 22:38 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| DEVYSER DIAGNOSTICS Aktie jetzt für 0€ handeln | |||||
| Di | Devyser Diagnostics AB: Devyser extends its transplant test to heart and lung patients | 1.766 | GlobeNewswire (Europe) | Devyser today announced that One Lambda Devyser Accept cfDNA, its test for monitoring kidney transplant patients, can now also be used after heart and lung transplantation. The new applications are... ► Artikel lesen | |
| 21.10. | Devyser Diagnostics AB: Devyser wins tender in Italy worth approximately SEK 5.7 million - doubling test volumes compared with previous agreement | 187 | GlobeNewswire (Europe) | Devyser Diagnostics AB, through its Italian subsidiary, has been awarded a renewed tender by Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico in Milan. The agreement covers the company's NGS... ► Artikel lesen | |
| 31.08. | Devyser Diagnostics AB: Devyser appoints Torben Thölix as the new Chief Commercial Officer | 578 | GlobeNewswire (Europe) | Devyser today announces the appointment of Torben Thölix as Chief Commercial Officer (CCO). Torben will lead Devyser's global commercial organization and join the executive management team, reporting... ► Artikel lesen | |
| 06.08. | Devyser Diagnostics AB: Devyser signs first commercial reagent rental agreement under Illumina collaboration in Italy | 559 | GlobeNewswire (Europe) | Devyser, a global leader in advanced molecular diagnostics, today announced the first commercial agreement under its Systems Integrator collaboration with Illumina. The agreement, signed with an Italian... ► Artikel lesen | |
| 20.07. | Devyser Q2 2026 slides: revenue dips on distributor issues, profit holds | 1 | Investing.com | ||
| 20.07. | Devyser: Umsatz im zweiten Quartal sinkt um 10,7 % wegen Lageranpassung bei Vertriebspartner | 1 | Investing.com Deutsch | ||
| 20.07. | Devyser Diagnostics Announces Increase In Q2 Bottom Line | 1 | RTTNews | ||
| 20.07. | Devyser Diagnostics AB: Devyser Diagnostics AB publishes quarterly report for the period April to June 2026 | 653 | GlobeNewswire (Europe) | "As previously announced, the second quarter was weaker than expected. Sales were negatively impacted by a temporary inventory adjustment by our single largest distributor. Underlying demand remains... ► Artikel lesen | |
| 02.07. | Devyser Diagnostics AB: Sales in the second quarter of 2026 weaker than expected | 234 | GlobeNewswire (Europe) | Devyser Diagnostics AB (publ) (the "Company" or the "Group") announces that its preliminary sales for the second quarter of 2026 are weaker than indicated by the information and conditions available... ► Artikel lesen | |
| 25.06. | Devyser Diagnostics AB: Devyser secures SEK 8.9M five-year tender and strengthens Italian position | 508 | GlobeNewswire (Europe) | Devyser, a leading provider of advanced genetic testing solutions, has been awarded a tender in Regione Basilicata, Italy, with a total value of SEK 8.9 million. The tender includes several of Devyser's... ► Artikel lesen | |
| 22.05. | Devyser Diagnostics AB: Devyser strengthens its executive management team - Niklas Axelsson appointed new CFO and Sabina Berlin transitions to a new role within the company | 272 | GlobeNewswire (Europe) | Devyser today announces that Sabina Berlin, current CFO, will transition to a new role with responsibility for Investor Relations and Corporate Compliance. At the same time, the company has appointed... ► Artikel lesen | |
| 06.05. | Devyser Diagnostics AB: Bulletin from the Annual General Meeting of Devyser Diagnostics AB (publ) held on 6 May 2026 | 274 | GlobeNewswire (Europe) | The Annual General Meeting of Devyser Diagnostics AB (publ) ("Devyser" or the "Company") was held on Wednesday, 6 May 2026 at Bränningevägen 12, 120 54 Årsta. The main resolutions passed at the Meeting... ► Artikel lesen | |
| 27.04. | Devyser Diagnostics AB: Devyser Diagnostics AB publishes quarterly report for the period January to March 2026 | 884 | GlobeNewswire (Europe) | "Devyser is reporting its fourth consecutive quarter with a positive operating result. This is an outcome we are delivering in an external environment that continues to present challenges: headwinds... ► Artikel lesen | |
| 07.04. | Devyser Diagnostics AB: Devyser announces that Chief Commercial Officer will leave the company | 287 | GlobeNewswire (Europe) | Devyser Diagnostics AB today announces that the company's Chief Commercial Officer (CCO), Theis Kipling, has decided to leave Devyser to take up a position with another company.
"During Theis' time... ► Artikel lesen | |
| 01.04. | Devyser Diagnostics AB: Devyser completes acquisition of CyberGene AB and carries out issue of compensation shares | 542 | GlobeNewswire (Europe) | Devyser Diagnostics AB (publ), a Swedish molecular diagnostics company, announces that the acquisition of all shares in CyberGene AB ("CyberGene") that was announced on 11 February 2026 has today been... ► Artikel lesen | |
| 04.03. | Devyser Diagnostics AB: Devyser launches the first IVDR compliant NGS assay for thalassemia and sickle cell disease testing | 534 | GlobeNewswire (Europe) | Devyser, today announced the launch of Devyser Thalassemia v2, the first Next-Generation Sequencing (NGS) assay for genetic analysis of thalassemia and sickle cell disease (SCD) available on the European... ► Artikel lesen | |
| 12.02. | Devyser Diagnostics AB: Devyser Diagnostics AB publishes year-end report for January to December 2025 | 615 | GlobeNewswire (Europe) | "The fourth quarter confirmed the positive earnings trend that we have seen throughout the year. Operating profit amounted to SEK 18.0 million (-3.7) for the quarter and to SEK 10.1 million (-62.3)... ► Artikel lesen | |
| 11.02. | Devyser Diagnostics AB: Devyser acquires Swedish company Cybergene AB and strengthens its position in the aneuploidy market | 1.017 | GlobeNewswire (Europe) | Devyser Diagnostics AB (publ), a Swedish molecular diagnostics company, today announces that it has entered into an agreement relating to the acquisition of 100 percent of the shares in Cybergene AB... ► Artikel lesen | |
| 28.01. | Devyser Diagnostics AB: Devyser enters Strategic Supply Agreement with Illumina to offer sequencing instruments and products | 796 | GlobeNewswire (Europe) | Devyser today announced that it entered a strategic agreement with Illumina, a global leader in DNA sequencing and array-based technologies, to provide Illumina sequencing instruments and related products... ► Artikel lesen | |
| 08.12.25 | Devyser Diagnostics AB: Devyser secures a four-year tender in France for Devyser Compact | 355 | GlobeNewswire (Europe) | Devyser, a leading provider of advanced genetic testing solutions, has been awarded a new tender in Marseille, France, valued up to SEK 9.5 million over a 48-month period.
This tender with Assistance... ► Artikel lesen |
1 2 Weiter >>
25 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| MEDTRONIC | 84,80 | +0,45 % | Medtronic Spark Scholarship Applications Now Open for Students Pursuing Careers in Healthcare Technology | Up to 100 scholarships will be awarded globally to students pursuing degrees or credentials in health tech fields. NORTHAMPTON, MA / ACCESS Newswire / October 28, 2026 / Medtronic, a global leader in... ► Artikel lesen | |
| HCA HEALTHCARE | 401,10 | -0,72 % | HCA Healthcare, Inc. Q3 Sales Increase | WASHINGTON (dpa-AFX) - HCA Healthcare, Inc. (HCA) announced earnings for third quarter of $1.579 billionThe company's bottom line came in at $1.579 billion, or $7.27 per share. This compares... ► Artikel lesen | |
| LANTHEUS | 89,80 | +0,56 % | Lantheus receives FTC second request on Curium deal | ||
| CAREDX | 65,50 | +2,34 % | BTIG raises CareDx stock price target to $81 on revenue outlook | ||
| ENVISTA | 21,400 | 0,00 % | Envista Q3 Earnings Ahead: Product Innovation to Drive Growth | ||
| GT BIOPHARMA | 5,630 | +0,90 % | GT Biopharma, Inc.: GT Biopharma Selected for Oral Presentation at the SITC 2026 Annual Meeting | ||
| SYNEOS HEALTH | - | - | Research Solutions, Inc.: Research Solutions Reports Fourth Quarter and Fiscal Year 2026 Results | Reports Record Fiscal Year Net Income of $2.8 Million, 14% YoY B2B ARR Increase and ARR of $22.5 Million
HENDERSON, Nev., Sept. 9, 2026 /PRNewswire/ -- Research... ► Artikel lesen | |
| CARMAT | - | - | CARMAT SAS: EFICAS Study Results Confirm the Clinical Performance of the Aeson Total Artificial Heart as a Bridge-to-Transplant Therapy | The study's primary endpoint was achieved in 72.7% of the 55 patients implanted between December 2022 and May 2025.
This rate was significantly above the historical benchmark of 38% established... ► Artikel lesen | |
| CHEMOMETEC | 81,95 | +0,80 % | Chemometec A/S: Major shareholder announcement - BlackRock, Inc. | ||
| POLAREAN IMAGING | 0,002 | 0,00 % | Polarean: Xenon MRI Advances as a Cardiopulmonary Biomarker Platform at ATS 2026 | ||
| ARRAIL GROUP | 0,203 | -100,00 % | ARRAIL GROUP (06639): FURTHER DELAY IN PUBLICATION OF OUTSTANDING FINANCIAL RESULTS AND POSTPONEMENT OF ANNUAL GENERAL MEETING AND CONTINUED SUSPENSION ... | ||
| PROMIMIC | 0,865 | +2,98 % | Promimic AB Q2 Sales Increase | ||
| SIEMENS HEALTHINEERS | 42,590 | +1,72 % | EQS-CMS: Siemens Healthineers AG: Veröffentlichung einer Kapitalmarktinformation | EQS Zulassungsfolgepflichtmitteilung: Siemens Healthineers AG
/ Bekanntmachung nach Art. 5 Abs. 1 lit. b), Abs. 3 der Verordnung (EU) Nr. 596/2014, zuletzt geändert durch die Verordnung... ► Artikel lesen | |
| FRESENIUS | 46,335 | +0,17 % | JEFFERIES stuft Fresenius SE auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat Fresenius auf "Buy" mit einem Kursziel von 55 Euro belassen. Die Gewinndynamik des Medizinkonzerns sollte sich im dritten Quartal fortgesetzt... ► Artikel lesen | |
| FRESENIUS MEDICAL CARE | 40,600 | +0,07 % | DZ BANK stuft FMC FRESENIUS MEDICAL CARE AG auf 'Kaufen' | FRANKFURT (dpa-AFX Analyser) - Die DZ Bank hat den fairen Wert für FMC von 54 auf 46 Euro gesenk, aber die Einstufung auf "Kaufen" belassen. Dass die US-Regierung die Behandlung von Nierenerkrankungen... ► Artikel lesen |
Das Unternehmen DEVYSER DIAGNOSTICS AB kann der Branche Gesundheitswesen zugeordnet werden. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 4,880 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu DEVYSER DIAGNOSTICS AB finden Sie auf Wallstreet Online.